Results: This study uncovered 61 genes that were significantly up-or downregulated more than 2.5-fold in acute samples relative to respective baselines. One of the most upregulated genes was ADM, which encodes the vasoactive peptide adrenomedullin. A stable ADM protein surrogate (pro-ADM) was markedly elevated in SCLS acute sera compared to remission samples or sera from healthy controls. Monocytes and endothelial cells (ECs) from SCLS subjects expressed significantly more ADM in response to proinflammatory stimuli compared to healthy control cells.
hemoconcentration (elevated hemoglobin and hematocrit), and serum hypoalbuminemia. 2, 3 The initial presenting signs and symptoms of SCLS are quite nonspecific. It remains a clinical diagnosis, and there are no unique biomarkers or diagnostic tests. For these reasons, many patients go years without the correct diagnosis. 4 It can be difficult to differentiate SCLS from sepsis upon initial presentation as either may present with fevers, elevated WBC count, hypotension, and hemoconcentration. However, sepsis is not typically associated with severe hypoalbuminemia and anasarca following the administration of IV fluids so profound that it results in compartment syndromes and therapeutic fasciotomies. Although elevated Hgb/Hct resulting from fever/dehydration in sepsis typically decrease following IV fluid administration, they tend to remain high for prolonged periods of time in SCLS due to the severity of vascular leakage. In anaphylaxis, a trigger can often be identified, and it is associated with allergic signs and symptoms, including urticaria, stridor, or wheezing, which are not present in SCLS. 3 Treatment of acute episodes is limited to support of vital organ functions through maintenance of circulating blood volume using intravenous fluids and vasopressors and renal replacement therapy as necessary to treat acute kidney injury that may result from intravascular volume depletion.
We have accrued a registry of 63 patients with a confirmed diagnosis of SCLS, which is currently among the largest cohorts in the world given that current worldwide prevalence is likely to be less than 150 cases. We demonstrated previously that proinflammatory mediators (e.g., IL-1 , IL-6, IL-8, CCL2, CXCL10, TNF ), and angiogenic proteins (vascular endothelial growth factor A, VEGF-A, and angiopoietin-2, Angpt-2) can be detected as transient spikes in sera of SCLS patients at the onset of flares, 5, 6 relative to levels detected in convalescent intervals. In addition, monocytes from SCLS subjects produced more CXCL10 compared to those from healthy controls, suggesting an overexuberant leukocyte response to proinflammatory mediators. Consistent with the importance of humoral mediators in the vascular barrier dysfunction associated with SCLS episodes, sera from SCLS subjects obtained during flares, but not during remission, reduced barrier integrity of normal endothelial cells (ECs) in culture and increased vascular permeability through mechanisms involving internalization of a junctional molecule, vascular endothelial cadherin (VE-Cadherin), and through increased actin stress fiber formation. 5 No biomarkers or pathogenic mediators unique to SCLS have yet been identified. We have initiated a search for such factors by analyzing gene expression patterns in PBMCs obtained from patients during acute episodes relative to PBMCs obtained during periods of disease remission. One of the most up-regulated genes, ADM, encodes a 52-amino acid secreted peptide originally isolated from human pheochromocytoma. ADM exerts powerful hypotensive effects due to vasodilation mediated by vascular smooth muscle relaxation, but its effects on vascular permeability are less clear. 7, 8 Because patients with acute SCLS often present with profound hypotension out of proportion to the initial degree of vascular leak (manifesting as clinically apparent edema), we hypothesized that ADM could contribute to the symptomatology associated with flares of the disease. In this study, we explored the potential sources of ADM in SCLS and its effects on vascular barrier function. 
TA B L E 1 Patient characteristics

METHODS
Subjects
SCLS patients were identified and diagnosed according to criteria described previously. 9 The demographics of the patients studied are summarized in Table 1 
Reagents and antibodies
Human microvascular ECs (HMVECs) and the U937 human monocyte cell line were purchased from ATCC. PMA was obtained from Sigma-Aldrich. The secretory transporter inhibitor monensin and the following antibodies were from Biolegend: phycoerythryin (PE)-Cy7 conjugated anti-CD14 and Brilliant Violet (BV605)-conjugated anti-CD3. PE-conjugated anti human CD19 was from BD Biosciences. Allophycocyanin-conjugated anti-ADM was from US Biological. Recombinant human ADM was purchased from GenScript, and human VEGF-A 165 was from PeproTech.
Microarray analysis
PBMCs were isolated from whole blood obtained by venipuncture at or near the onset of an acute SCLS crisis and from the same patient during a convalescent interval. RNA was extracted using the RNAeasy kit (Qiagen) and subjected to microarray analysis using the Human WG Expression Array (Illumina BeadChip) according to the manufacturer's instructions. The complete array dataset was deposited into the Gene Expression Omnibus (GEO) databank (Accession number: GSE97287).
Data were analyzed using Partek Genomics Suite, and statistical significance determined using 2-way ANOVA.
Cell isolation and stimulation
Monocytes were isolated from PBMCs using a negative selection magnetic bead protocol (Pan Monocyte Isolation Kit; Miltenyi). The purity of monocyte preparations was assessed by flow cytometry using CD14 antiboy and was typically >90%. Blood outgrowth endothelial cells (BOECs) were generated as described previously 10 
Proteome profiler array
Cytokine components of RW medium were analyzed by Proteome Profiler Array (R&D Systems), according to manufacturer's guidelines.
Flow cytometry
PBMCs were left untreated or treated with RW medium (10% vol/vol) or LPS (100 ng/mL) in serum-free medium supplemented with 0.1%
BSA for 24 h in the presence of monensin, followed by antibody staining of both intracellular and cell surface markers as described. 6 Cell staining was analyzed using an LSRII flow cytometer (BD BioSciences) and FlowJo software. 
Quantitative real-time PCR
Pro-ADM ELISA
Plasma pro-ADM levels were analyzed by ELISA (MyBioSource)
according to the manufacturer's instructions.
Impedance measurements
Impedance measurements were used to assess endothelial barrier function. Electrical resistance was measured across HMVEC monolayers at 4,000 Hz using the Electric Cell-substrate Impedance Sensing (ECIS) Z apparatus (Applied BioPhysics) as described previously. 5 Briefly, HMVECs were serum starved in EBM plus 0.2% BSA for 5 h, and ADM was added as a 10× stock solution in the same medium. Medium alone was used as the control. Data were collected from 2 replicates per condition in each experiment.
Paracellular permeability assays
HMVECs ( 
Immunofluorescence
HMVECs were grown to confluency on 0. 
Statistics
qPCR and ELISA data were analyzed with the GraphPad Prism 7 software package. Non-parametric tests were used for analysis of patient samples (Mann-Whitney test for analysis of 2 groups;
Kruskal-Wallis for analysis of multiple groups). Two-way ANOVA was used to analyze impedance measurement data, and microarray data was analyzed using Partek Genomic Suite. P values < 0.05 were considered significant.
F I G U R E 1
HeatMap of significantly altered genes in SCLS subjects during disease flares relative to disease quiescence. (A) PBMCs from 12 SCLS subjects, obtained during either remission (basal) or acute (episodic) phases, were isolated from peripheral blood. RNA was extracted and subjected to microarray analysis as described in section Methods. Sixty-one genes were significantly changed for at least 2.5-fold by 2-way ANOVA, as shown in the Hierarchical Clustering HeatMap (A) (P < 0.05). y-axis is color coded to indicate basal (green) or acute episodic (red) samples. (B) Ingenuity pathway analysis of transcriptome analysis of acute versus basal PBMCs graphed by Benjamini-Hochberg corrected P value. Dash P = 0.05; Mq, macrophage
RESULTS
Transcriptomic profiling of PBMCs from SCLS subjects
SCLS is a chronic relapsing/remitting disease of unknown etiology.
Patients have no residual symptoms at baseline yet experience recurrent and transient episodes of hypotension followed by massive peripheral edema typically confined to the peripheral extremities.
Because the clinical history and our prior analysis of SCLS sera indicated a role for inflammatory mediators in the induction of acute SCLS, 5, 6 we hypothesized that flares result from an aberrant leukocyte response to one or more of these inflammatory stimuli, Fig. 2A) . Baseline ADM expression did not differ significantly in
PBMCs from asymptomatic SCLS subjects or healthy controls (Fig. 2B ).
Pro-ADM levels are markedly increased in acute SCLS sera
To evaluate the role of ADM in acute SCLS, we first analyzed ADM protein levels in sera. Circulating ADM is highly unstable with a serum half-life of approximately 20 min. 11 To overcome this hurdle, we measured levels of pro-ADM, a biologically inactive yet chemically stable mid-region precursor of ADM that is released together with ADM at a 1:1 ratio; has a half-life of several hours; and has been used as a surrogate for ADM in other diseases. 12,13 Serum pro-ADM levels were significantly elevated in acute SCLS sera compared with either convalescent SCLS sera or sera from healthy controls (Fig. 3A) . There appeared to be 2 distinct groups: one with relatively high pro-ADM levels during the acute phase, and another with significantly lower values (P < 0.0001, Mann-Whitney). We found previously that many serum factors peak relatively early in the course of an SCLS flare but decrease rapidly during the course of the episode. 5 As most acute samples were sent to us from offsite locations, variations in the timing of sample collection relative to disease symptoms (i.e., episode onset vs. mid-episode) could account for these differences as we have seen a rapid decline in cytokine levels (e.g., VEGF-A) after the onset of an episode. 5 In addition, at the time of acute sample collection, 6 out of 8 patients in the ADM lo group were experiencing an attack of mild clinical severity, which may have resulted in lower peak values. Even taking these factors into account, ADM levels during flares were much higher than in matched remission samples in nearly all patients (15 out of 18). Serum pro-ADM levels increased at least 5-fold during a flare relative to asymptomatic intervals in more than half of the subjects (8 out of 15) (Fig. 3B) .
F I G U R E 4 ADM expression in leukocytes and ECs in SCLS. (A and B)
ADM expression was assessed in purified monocytes (A) or blood outgrowth ECs (BOEC, B) from SCLS or controls by qPCR. Cells were left untreated or stimulated with 10% RW medium for 24 h prior to RNA extraction and cDNA synthesis. Plots in (A) show mean ± SEM of 6-8 subjects/group. In (B), values are the relative expression in stimulated cells relative to unstimulated cells in each group ("fold basal"). *P = 0.04, 2-way ANOVA
Monocytes and ECs from SCLS subjects express more ADM in response to inflammatory mediators
Our studies so far demonstrated increased ADM expression in PBMCs of SCLS subjects and increased serum pro-ADM levels during disease flares. Previous studies have shown that monocytes and ECs are abundant sources of ADM. [14] [15] [16] We hypothesized that inflammatory mediators present during acute SCLS attacks induce ADM secretion by monocytes and/or ECs. We assessed ADM expression in peripheral blood monocytes and BOECs at baseline and following treatment with an inflammatory stimulus. To mimic the cytokine storm surrounding SCLS crises, we treated cells with supernatants from PMAstimulated U937 monocytes. By proteomic analysis, we found that this reagent ("RW") is enriched in many of the same inflammatory mediators present in acute SCLS sera including CCL2, TNF , IL-8, and IL-1 5, 6 relative to medium alone (Supplemental Fig. S1 ). RW medium or LPS, but not individual SCLS-associated mediators Angpt-2, CXCL10, IFN , or CCL2, alone or in combination, induced a robust increase in ADM expression in both monocytes and BOECs over a period of 6-48 h (Supplemental Fig. S2 ). Purified monocytes from SCLS subjects expressed similar amounts of ADM as did those from healthy controls at baseline but significantly more ADM in response to stimulation with RW medium, matching microarray results (Fig. 4A) . Similarly, RW medium induced significantly more up-regulation of ADM expression in BOECs from SCLS subjects compared to those from healthy controls (2.54-fold vs. 1.62-fold increase over unstimulated cells; Fig. 4B ). Cellular receptors for ADM consist of the corticotropin releasing hormone like receptor, which has several endogenous ligands, complexed to coreceptors of the receptor activity modify protein (RAMP) family. 17 We analyzed expression of RAMP2 by qPCR in BOECs and monocytes as this coreceptor for CRLR is most specific for ADM. 18 However, we found no significant difference in RAMP2 expression in SCLS and healthy donor-derived cells, either at baseline or in response to proinflammatory stimuli (Supplemental 
ADM promotes vascular endothelial barrier function
Whereas previous studies have indicated that ADM induces endothelial proliferation and angiogenesis, 19 its effects on endothelial permeability in vivo have not been fully characterized although several studies have shown beneficial effects on barrier integrity. 15, 20, 21 To examine this issue further, we measured electrical resistance across monolayers of normal microvascular ECs (HMVECs). We found that stimulation of these cells with ADM enhances barrier function in a dose-dependent manner, as reflected by significantly increased resistance (Fig. 6A) . Furthermore, the concurrent treatment of
HMVECs with ADM and VEGF-A prevented the transient increase in and C). In contrast, treatment of HMVEC monolayers with RW medium induced a more gradual increase in permeability (Fig. 6D) . Application of ADM to cells treated with RW medium for 18 hours resulted in a short-lived increase in resistance that diminished over the next several hours (Fig. 6E) . Thus, ADM can transiently reverse permeability induced by proinflammatory mediators in this assay.
In order to better characterize what type of permeability is affected, we performed paracellular flux assays using fluorescently conjugated dextrans of different molecular weights. We tracked the flux of these conjugates over time across HMVEC monolayers plated in wells containing Transwell inserts. We focused on ADM's effect on thrombininduced permeability as this stimulus gave the most robust increase in permeability in these assays. We found that thrombin stimulation To clarify the mechanisms underlying this phenotype, we analyzed the effect of ADM on VEGF-A-mediated VE-cadherin expression at cell junctions and F-actin formation by immunofluorescence. HMVEC monolayers treated with medium alone displayed nearly continuous VE-cadherin immunoreactivity at cell junctions (Fig. 7A) . In response to VEGF-A, expression of VE-cadherin on cell membranes was markedly decreased and accompanied by gaps between adjacent cells and modestly increased central actin stress fibers. Treatment of cells with ADM alone stabilized junctional VE-cadherin expression and increased peripheral (cortical) F-actin, which is predicted to fortify the vascular barrier. 22 Concurrent application of ADM and VEGF significantly reduced the effect of VEGF-A on VE-cadherin disruption but had little effect on F-actin (Fig. 7B) . These results indicate that ADM affects EC morphology at baseline and in the presence of a canonical endothelial permeability-increasing protein, VEGF-A that promote vascular barrier function. Other ADM-inducing factors may include proinflammatory cytokines. Our previous analysis of SCLS sera revealed an array of proinflammatory mediators associated with SCLS flares including interleukins and chemokines. 5, 6 Monocytes adhere to vascular endothelium in response to chemokines, which may activate both monocytes and ECs and lead to ADM secretion. Although no obvious leukocytoclastic vasculitis has been identified in the small number of skin biopsies that have been done on SCLS patients during remission, 1 study demonstrated perivascular mononuclear infiltrates in a skin biopsy taken during an episode. 3, 26 ADM is expressed widely and is involved in many physiological processes including angiogenesis, vascular tone, embryonic development, and inflammation. 7, 19, 27 A prominent physiological function of ADM is to reduce mean arterial pressure blood pressure through cAMP generation and activation of eNOS. 19, 27 Although ADM surges might contribute to hypotension in acute SCLS by modulating vascular tone, the role of ADM in maintaining the integrity of blood vessels primarily involved in SCLS (e.g., skin and skeletal muscle) in vivo remains unclear.
In a previous study, short-term (1 h) incubation of HMVECs with ADM reduced flux of FITC-albumin through Transwell filters over time, suggesting a barrier-fortifying effect. 21 On the other hand, Vascular leakage syndrome models in mice have been described, including those induced by cytokines (IL-2 or IL-21). 30 In addition,
Clarkson originally reported that plasma obtained from his index patient obtained at the peak of an episode induced a shock-like syndrome in rats. 31 Based on these and other findings, it may be possible to develop an animal model of SCLS induced by SCLS plasma or specific mediators contained therein. However, IL-2 is not increased in sera from SCLS patients in the midst of acute episodes as described in our previous studies. 5, 6 Secondly, IL-2 or IL-21 induces vascular leakage in both lung and liver, 30 2 organs that do not appear to be affected in SCLS. Future studies will determine relevant mediators promoting an SCLS-like disease in mice and test the role of ADM in such models, through measurements of ADM levels in serum, evaluation of ADM expression in leukocytes, and examination of the therapeutic benefit of ADM blockade.
Further studies including measurements of pro-ADM levels over the course of an SCLS episode and cross-comparison of levels in SCLS and other diseases such as sepsis will be needed to determine whether or not ADM levels will be useful to predict the onset of flares of SCLS, evaluate disease progression, or assess efficacy of therapeutic interventions. For example, as warning signs and/or a characteristic prodrome seldom precede SCLS crises prior to the sudden onset of frank shock, monitoring of pro-ADM levels during periods of high risk (e.g., infections) might be used to assess the need for acute therapeutic intervention, for example, intravenous immunoglobulin infusion therapy, which has been shown to mitigate the severity of SCLS episodes. 32 Similarly, monitoring of pro-ADM levels during convalescent intervals could represent a biomarker of disease progression in the absence of overt crises in patients with frequent, but less severe episodes. Finally, targeting ADM-related pathways (e.g., NO), might be viable to treat vasopressor-resistant hypotension that is frequently seen in acute SCLS. In support of the hypothesis, a recent case report demonstrated the efficacy of administration of methylene blue, a NO scavenger, in reversing hypotension in a critically ill patient with SCLS. 33 In summary, our results suggest that surges of ADM in acute SCLS represent a feedback compensation mechanism that can thwart the actions of permeability mediators abundant in the circulation. ADM levels are increased in many diseases including sepsis, cardiovascular disease, hypertension, heat failure, and systemic inflammatory response syndrome, 13 ,34 yet levels in SCLS are equivalent or even 
